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Epilepsy Pipeline Conference Summary
Daniel J. Abrams, MD
CEO of Cerebral Therapeutics, LLC

Each year the Epilepsy Therapy Project in conjunction with the Epilepsy Foundation puts on a conference for new development in diagnostics, device and
medication therapies emerging in the field of epilepsy. We summarize below a
few of the presentations that we thought would be of interest to the JHN readership. For a full listing of the presentations please see http://www.epilepsy.com/
accelerating-new-therapies/2016-epilepsy-pipeline-conference.
In the new mechanism of action therapies there were three new products that were
presented. Scotts Edwards updated the conference on progress of the compound
SF0034 which a potent and selective KCNQ2/3 activator designed to suppress neuronal
hyperexcitability in patients with partial-onset epilepsy. SF0034 was found to have
significantly greater potency and selectivity in preclinical models of epilepsy compared
with the known product ritagabine. Tansna President Mark Robbins, presented progress
fir a new novel non-sedating agent derived from propofol which in early work had a
favorable efficacy and side effect profile. Michael Ragowski presented on a new Inhaled
treatment for refractory epilepsy, which is a prodrug of propofol, as a potential rescue
for patients having seizures and want to try and avoid the oncoming seizure. Lastly
and for a similar target, Jackie French presented data on Phase 2a for a status epileptic
rescue medication that being developed by Alexza Pharmaceuticals for patients who
have repetitive seizures and want to stop after the first seizure.
On the diagnostic side, Rosalind Picard from MIT an affective computing expert,
presented Empatica’s increasing experience with epilepsy watch data primarily for
patients generalized tonic clinic seizures. In the newcomer competition, several exciting
new companies presented, Aswin Gunasekar the CEO of Zeto presented his companies
new EEG device designed to make ambulatory EEG quicker, cheaper, more accurate,
with less need for an EEG technician and potentially simplifying EEG review consultation by an off site Neurologist. The presentation consisted of having individuals try

the prototype. It was clearly a significant
improvement over what is available and
generated a buzz amongst clinicians and
early stage investors.
Regarding providing medical services side
for epilepsy, EpiNightNurse an Internetbased system for nightly video and audio
monitoring of patients with epilepsy
was presented by Tamara and Joachim
Coche, parents of a son with epilepsy
from Scandinavia. The system consists
of a real time video recording of a patient
at night being viewed by specially trained
epilepsy nurses in the Philippines who
can then communicate back with caregivers. Essentially the Coche’s created
a business of a new system of care for
epilepsy patients and monitoring and
demonstrated how it works. Using time
differences and technology they developed a method for an adjunctive way to
monitor patients and it will be exciting to
see how it grows and develops.
It is great for patients and physicians with
epilepsy who are in need of new therapies
that this annual conference occurs. We
encourage you to attend and be involved
if you can as the evolution and changes
in the field are exciting to see first hand.

sEEG and Epilepsy
Surgery Symposium
October 21 and 22 | Philadelphia, PA
Join a discussion for the latest trends and controversies in
sEEG and epilepsysurgery. Topics include laser ablation,
vagal nerve stimulation, responsive neurostimulation and
an in-depth analysis of sEEG strategies. This is an accredited
CME course designed for epilepsy neurosurgeons and
epileptologists.
To register: WillsEye.org/continuing-medical-education
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